Senseonics, Inc.
12
2
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature
Role: lead
ROME GS System Study
Role: lead
Eversense® Non-adjunctive Use Post Approval Study
Role: lead
Post Approval Study of the Eversense® Continuous Glucose Monitoring
Role: lead
Evaluation of the Eversense Continuous Glucose Monitoring System in Type I Diabetic Youth
Role: collaborator
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
Role: lead
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
Role: lead
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
Role: lead
Evaluation of the Accuracy of an Implanted Glucose Sensor
Role: lead
A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System in Canada
Role: lead
Home Use Sensor Study
Role: lead
PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor
Role: lead
All 12 trials loaded